Abstract:OBJECTIVE:Allogeneic bone marrow transplantation has been established as a standard method for the treatment of a range of malignant and non-malignant hematologic diseases in children. Unfortunately, fewer than 30% of patients have a human leukocyte antigen (HLA)-matched sibling. Advances in our understanding of the HLA system and the development of large international donor registries encourage the increasing use of unrelated donors as an alternative source of stem cells. The purpose of this study was to evaluate the clinical efficacy and safety of unrelated donor allogeneic bone marrow transplantation (URD-BMT) for the treatment of childhood leukemia.METHODS:Six patients with leukemia received URD-BMT. Two of them suffered from chronic myeloid leukemia (CML), 3 suffered from acute lymphocytic leukemia (ALL) and 1 suffered from acute promyelocytic leukemia (APL) (CR2). All cases were facilitated by Tzu Chi Marrow Donor Registry (TCTMDR). The high resolution DNA test for classIand II was carried out in HLA typing of all donor-receiver pairs. HLA allele matched in three cases, mismatched with one locus in two cases and with two loci in one case. All patients were prepared with cyclophosphamide (CY) 60 mg/kg/day for 2 days (total dose 120 mg/kg) and busulfan (Bu) 1 mg/kg x 4/day for 4 days (total dose 16 mg/kg). Mycophenolate mofetil (MMF), CsA and MTX were given to prevent acute graft-versus-host-disease (aGVHD). CsA of 3 mg/kg/d was continuously given by i.v. infusion, and then 6mg/kg/d by oral. The blood CsA concentration was 200 - 300 ng/ml. MTX was given at the dosage of 15 mg/m(2) on d 1 and 10 mg/m(2) on d 3, 6,9 or 11. MMF was given at the dosage of 0.25 - 0.5 g/d from day 0 to day 120. Prostaglandin E1 was given to prevent the hepatic veno-occlusive disease (VOD), Ganciclovir was used to prevent CMV infection until the CMV antigenemia became negative.RESULTS:Analysis of DNA short tandem repeats showed total engraftment of donor marrow after transplantation in all cases. The median time when granulocyte exceeded 0.5 x 10(9)/L was 14.5 (13 - 18) days, platelets exceeded 20 x 10(9)/L was 16 (14 - 23) days. The acute GVHD grade II-IV occurred in 2 of 6 (33.3%) patients. There were 3 cases with chronic GVHD and none of them developed with the extensive chronic GVHD. All patients were alive in disease-free situation now with median follow-up 412 (187 - 1338) days.CONCLUSION:URD-BMT is an effective method for the treatment of childhood leukemia.

Management with crossmatch-compatible platelets for a pediatric neuroblastoma-associated thrombocytopenia patient with anti-HLA antibodies： a case report

Predictive Value of Plasma IL-1 Β, IL-8 Levels and Clinical Factors for Platelet Transfusion Refractoriness in Patients with Pediatric Cancer

Platelet HLA gene bank digital matching technology for platelet transfusion refractory patients with malignant tumors: a case report

Analysis of Platelet‐reactive Alloantibodies and Evaluation of Cross‐match‐compatible Platelets for the Management of Patients with Transfusion Refractoriness

Treatment of Childhood Leukemia with Unrelated Donor Allogeneic Bone Marrow Transplantation

Genetic Polymorphisms of HPA 1-6, 15 Systems in the Hangzhou Population and Their Role in the Management of Platelet Transfusion Refractoriness

Plasma Exchange-Based HLA Antibody Clearance Overcome Primary Graft Failure and Platelet Transfusion Refractoriness in a Myelodysplastic Syndrome Patient: A Case Report and Review of the Literature

Exploration of HLA-matched Platelet Units in HLA-immunized PTR: a Retrospective Study of Patients with Hematological Disorders

Improving platelet function following prophylactic platelet transfusion in patients with hematological malignancies

Advances in Human Leukocyte Antigen Testing Technologies and Management Strategies for Platelet Transfusion Refractoriness

Platelet Engraftment in Patients with Hematologic Malignancies Following Unmanipulated Haploidentical Blood and Marrow Transplantation: Effects of Cd34(+) Cell Dose and Disease Status

Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia

The treatment and mechanism of platelet transfusion refractoriness in pediatric hematological disorders

Transfusion‐induced Platelet Antibodies and Regulatory T Cells in Multiply Transfused Patients

Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management

Establishment and Clinical Application of the Hla Genotype Database of Platelet-Apheresis Donors in Suzhou

Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics

Platelet transfusions: the problem of refractoriness

Establishment and Clinical Application of Platelet Donor Registry with Known HLA Class Ⅰ and HPA Type in Qingdao Area, China

[The Effect of Immunized Platelet Transfusion Refractoriness on Allo-HSCT Patients with Malignant Hematological Diseases].

Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome